References
- Bleiberg, H. and Rothenberg, M. L. CPT-11: From DNA topology to clinical activity. Semin. Oncol. 1996, 23, 1-50
- Dahut, W., Harolod, N., Takimototo, C., Allegra, C., Chen, A., Hamilton, J. M., Arbuck, S., Sorensen, M., Grollman, F., Nakashima, H., Lieberman, R., Liang,M., Corse, W. and Grem, J. Phase I and pharmacokinetic study of 9-aminocamptothecin given as a 72-hour infusion in adult cancer patients. J. Clin.Oncol. 1996, 14, 1236-1244
- Gottlieb, J. A., Guarino, A., Call, J. B., Oliverio, V. T. and Block, J. B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC100880). Cancer Chemother. Rep. 1970, 54, 461-470
- Hashimoto, H., Chatterjee, S. and Berger, N. A. Mutagenic activity of topoisomerase I inhibitors. Clin. Cancer Res. 1995, 1, 369-376
- Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K. and Kingsbury,W. D. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 1989, 32, 715-720
- Iyer, L. and Ratain, M. J. Clinical pharmacology of camptothecins. Cancer Chemother. Pharmacol. 1998, 42, S31-S43
- KFDA. Guidelines for Toxicity Studies of Drugs. Notification No. 1999-61, Korea Food and Drug Administration, Seoul, 1999
- Kim, E. J., Lee, R. K., Suh, J. E., Han, S. S. and Kim, J. K. Safety pharmacology of CKD-602, a novel anticancer agent. Arzneimittel forschung. 2003, 53, 272-279
- Kim, J. C., Kim, S. H., Shin, D. H., Ahn, T. H., Kim, H. C., Kim, Y. B., Jiang, C. Z., Han, J. and Chung, M. K. Effects of prenatal exposure to the environmentalpollutant 2-bromopropane on embryo-fetal development in rats. Toxicology. 2004, 196, 77-86
- Kim, J. C., Shin, D. H., Ahn, T. H., Kang, S. S., Song, S. W., Han, J., Kim, C. Y., Ha, C. S. and Chung, M. K. 26-Week repeated oral dose toxicitystudy of the new quinolone antibacterial DW-116 in Sprague-Dawley rats. Food Chem. Toxicol. 2003, 41, 637-645
- Kim, J. H., Lee, S. K., Lim, J. L., Shin, H. J. and Hong, C. I. Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemicalcharacterization and hydrolytic equilibrium kinetics. Int. J. Pharm. 2002, 239, 207-211
- Kolimannsberger, C., Mross, K., Jakob, A., Kanz, L. and Bokemyer, C. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999, 56, 1-12
- Lee, J. H., Lee, J. M., Kim, J. K., Ahn, S. K., Lee,S. J., Kim, M. Y., Jew, S. S., Park, J. G. and Hong, C. I. Antitumor activity of 7-[2-(N-isopropylamino) ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res. 1998, 21, 581-590
- Lee, J. H., Lee, J. M., Lim, K. H., Kim, J. K., Ahn, S. K., Bang, Y. J. and Hong, C. I. Preclinical and phase I clinical studies with CKD-602, a novel camptothecin derivative. Ann. N. Y. Acad. Sci. 2000, 922, 324-325
- Moertel, C. G., Schutt, A. J., Reitmeier, R. J. and Hahn, R. G. Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinalcancer. Cancer Chemother. Rep. 1972, 56, 95-101
- OECD. Guidelines for the testing of chemicals. No. 401: Acute Oral Toxicity, aris, Organisation for Economic Co-operation and Development. Adopted 24Feb. 1987
- Ogawa, M. Novel anticancer drugs in Japan. J. Cancer Res. Clin. Oncol. 1999, 125, 134-140
- O'Leary, J. and Muggia, F. M. Camptothecins: a Review of their development and schedules of administration. Eur. J. Cancer. 1998, 34, 1500-1508
- Pizzolato, J. F. and Saltz, L. B. The camptothecins. Lancet. 2003, 361, 2235-2242
- Pratesi, G., Tortoreto, M., Corti, C., Giardini, R. and Zunino, F. Successful local regional therapy with topotecan of intraperitoneally growing human ovariancarcinoma xenografts. Br. J. Cancer. 1995, 71, 525-528
- Slichenmyer, W. J. and Rowinsky, E. K. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 1993, 85, 271-291
- Takimoto, C. H., Wright, J. and Arbuck, S. G. Clinical applications of the camptothecins. Biochim. Biophys. Acta. 1998, 1400, 107-119
- The european agency for evaluation of medicinal products. CPMP/709/96, Committee for proprietary medicinal products european public assessment report(EPAR), HYCAMTIN International Non-proprietary Name (INN): Topotecan (Abstract), 1996